Evidence map›Paper›PMID 39995075›Full record

ReviewThe European journal of neuroscience2025

Peripherin, A New Promising Biomarker in Neurological Disorders.

Carlo Manco, Delia Righi, Guido Primiano, Angela Romano, Marco Luigetti, Luca Leonardi, Nicola De Stefano, Domenico Plantone

Abstract readReview
In one paragraph

Review in The European journal of neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carlo MancoCentre of Precision and Translational Medicine, Department of Medicine, Surgery, and Neuroscience, University of Siena, Siena, Italy.ORCID 0000-0003-4572-2616
Delia RighiDepartment of Neurosciences, Sensory Organs and Thorax, Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Guido PrimianoDepartment of Neurosciences, Sensory Organs and Thorax, Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Angela RomanoDepartment of Neurosciences, Sensory Organs and Thorax, Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Marco LuigettiDepartment of Neurosciences, Sensory Organs and Thorax, Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Luca LeonardiNeuromuscular and Rare Disease Centre, Neurology Unit, Sant'Andrea Hospital, Rome, Italy.
Nicola De StefanoCentre of Precision and Translational Medicine, Department of Medicine, Surgery, and Neuroscience, University of Siena, Siena, Italy.
Domenico PlantoneCentre of Precision and Translational Medicine, Department of Medicine, Surgery, and Neuroscience, University of Siena, Siena, Italy.ORCID 0000-0001-6666-7244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripherin is a class III intermediate filament protein that has recently gained attention as a potential biomarker for axonal damage in the peripheral nervous system. This review examines peripherin gene expression, protein structure, and its functions in both healthy and diseased states. Peripherin is predominantly expressed in the peripheral nervous system, especially in motor and sensory neurons, and plays a critical role in neurite growth, stability, and axonal transport during myelination. Its expression is regulated by various cytokines and undergoes several post-transcriptional modifications. Peripherin interacts with multiple proteins, including neurofilaments and kinases, influencing cytoskeletal dynamics and neuronal functions. The review also explores peripherin involvement in several neurological disorders, such as Amyotrophic Lateral Sclerosis, where its abnormal expression and aggregation contribute to disease pathology. Additionally, peripherin has been linked to polyneuropathies, traumatic axonal injury, and diabetic neuropathy, suggesting its broader relevance as a biomarker in these conditions. The potential of peripherin as a biomarker is further supported by recent studies using ultrasensitive detection methods, which have identified elevated peripherin levels in the serum of patients with neurological diseases. Despite the promising findings, the application of peripherin as a biomarker in clinical settings remains limited, primarily due to challenges in its detection and the need for further validation in diverse patient populations. Future research directions include the development of more sensitive assays and the exploration of peripherin's role in non-neuronal tissues, which may expand its diagnostic and therapeutic potential.

Indexed as

Nervous System DiseasesPeripherinsAnimalsBiomarkersHumansBiomarkersPeripherinsamyotrophic lateral sclerosisbiomarkerneurofilamentsPeripherinpolyneuropathy

Identifiers

PMID39995075
PMCPMC11851000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.